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Abstract
Asthma represents a profound worldwide public health problem. The most effective anti-asthmatic
drugs currently available include inhaled β2-agonists and glucocorticoids and control asthma in
about 90-95% of patients. The current asthma therapies are not cures and symptoms return soon
after treatment is stopped even after long term therapy. Although glucocorticoids are highly
effective in controlling the inflammatory process in asthma, they appear to have little effect on the
lower airway remodelling processes that appear to play a role in the pathophysiology of asthma at
currently prescribed doses. The development of novel drugs may allow resolution of these changes.
In addition, severe glucocorticoid-dependent and resistant asthma presents a great clinical burden
and reducing the side-effects of glucocorticoids using novel steroid-sparing agents is needed.
Furthermore, the mechanisms involved in the persistence of inflammation are poorly understood
and the reasons why some patients have severe life threatening asthma and others have very mild
disease are still unknown. Drug development for asthma has been directed at improving currently
available drugs and findings new compounds that usually target the Th2-driven airway inflammatory
response. Considering the apparently central role of T lymphocytes in the pathogenesis of asthma,
drugs targeting disease-inducing Th2 cells are promising therapeutic strategies. However, although
animal models of asthma suggest that this is feasible, the translation of these types of studies for
the treatment of human asthma remains poor due to the limitations of the models currently used.
The myriad of new compounds that are in development directed to modulate Th2 cells recruitment
and/or activation will clarify in the near future the relative importance of these cells and their
mediators in the complex interactions with the other pro-inflammatory/anti-inflammatory cells and
mediators responsible of the different asthmatic phenotypes. Some of these new Th2-oriented
strategies may in the future not only control symptoms and modify the natural course of asthma,
but also potentially prevent or cure the disease.
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Asthma represents a profound worldwide public health
problem. The most effective anti-asthmatic drugs cur-
rently available include inhaled β2-agonists and glucocor-
ticoids and control asthma in about 90-95% of patients.
However, the future therapies will need to focus on the 5-
10% patients who do not respond well to these treatments
and who account for ∼50% of the health care costs of
asthma [1,2]. Strategies for the primary prevention of
asthma remain in the realm of speculation and hypothesis
[3]. Drug development for asthma has been directed at
improving currently available drugs and findings new
compounds that usually target the Th2-driven airway
inflammatory response. Several new compounds have
been developed to target specific components of the
inflammatory process in asthma [e.g. anti-IgE antibod-
ies(omalizumab), cytokines and/or chemokines antago-
nists, immunomodulators, antagonists of adhesion
molecules)], although they have not yet been proven to be
particularly effective. In fact only omalizumab has
reached the market where it may be most cost-effective in
those patients with severe persistent asthma and frequent
severe exacerbations requiring hospital care [3-5]. In this
chapter we will review the role of current antiasthma
drugs and future new chemical entities able to target Th2
cells in asthmatic airways. Some of these new Th2-ori-
ented strategies may in the future not only control symp-
toms and modify the natural course of asthma, but also
potentially prevent or cure the disease.
Effects of current antiasthma drugs on Th2 cells 
in asthmatic airways
Despite the large number of controlled clinical studies on
the effect of many antiasthma drugs (particularly inhaled
glucocorticoids) in suppressing airway inflammation in
asthmatics, there is a complete absence of controlled clin-
ical studies on the effect of these drugs on the Th2/Tc2
lymphocytes ratio in the airways of asthmatic patients. In
particular it is still unknown if inhaled glucocorticoids
can decrease the recruitment of Th2 lymphocytes and/or
the degree of their differentiation and/or activation.
In vivo animal models of asthma, particularly murine,
have been increasingly used to investigate the efficacy of
several anti-asthma drugs, including their effect on Th2
lymphocytes. However, animal models of asthma have
limitations; most are models of acute allergen exposure
which are sensitive to anti-interleukin(IL)-5 strategies;
animals do not spontaneously develop asthma and no
model mimics the entire asthma phenotype [6]. For these
reasons, the results obtained in animal models of asthma
must be confirmed with controlled clinical trials in asth-
matic patients.
Effects of glucocorticoids on Th2 cells
Inhaled glucocorticoids are the only anti-asthma agents
that clearly reverse the specific chronic airway inflamma-
tion present in asthma. Inhaled glucocorticoids have anti-
inflammatory effects in the airway of patients with asthma
[3]. In patients treated with inhaled glucocorticoids there
is a marked reduction in the number of mast cells, macro-
phages, T-lymphocytes, and eosinophils in the sputum,
bronchoalveolar lavage (BAL) and bronchial wall [7,8].
Furthermore, glucocorticoids reverse the shedding of epi-
thelial cells, the mucus-cell hyperplasia and basement-
membrane thickening characteristically seen in biopsy
specimens from patients with asthma [7,8]. However
some inflammation still persists in the airways of patients
with asthma who have poor airway function, despite reg-
ular and prolonged treatment with high doses of inhaled
or systemic glucocorticoids [8,9]. The inflammatory com-
ponent of asthmatic airways most responsive to glucocor-
ticoid treatment seems to be eosinophilic inflammation.
In patients with persistent asthma, well controlled taper-
ing of inhaled glucocorticoids induces an exacerbation
within a few months. This is usually associated with a
reversible increase of eosinophilic airway inflammation.
Some patients with difficult-to-control asthma may
develop exacerbations despite treatment with inhaled glu-
cocorticoids, and these often appear to have an eosi-
nophil-independent inflammatory mechanism [8,9].
Glucocorticoids also have direct inhibitory effects on
many of the cells involved in airway inflammation in
asthma, including macrophages, T-lymphocytes, eosi-
nophils, mast cells, and airway smooth muscle and epi-
thelial cells. In vitro, glucocorticoids decrease cytokine
mediated survival of eosinophils by stimulating apopto-
sis.
This process may explain the reduction in the number of
eosinophils, particularly low density eosinophils, in the
circulation and lower airways of patients with asthma dur-
ing glucocorticoid therapy. Inhaled glucocorticoids atten-
uated the allergen-induced increase in peripheral blood
eosinophils and on eosinophil/basophil colony-forming
units (Eo/B CFU) [7,8]. They also significantly attenuated
the baseline, but not allergen-induced increase, numbers
of total CD34(+) cells, CD34(+)IL-3Rα+ cells and inter-
leukin (IL)-5-responsive Eo/B-CFU in the bone marrow.
Glucocorticoids may not inhibit the release of mediators
from mast cells, but they do reduce the number of mast
cells within the airway [7,8]. CD4+ and CD8+ T lym-
phocytes in peripheral blood of asthmatic patients are in
an activated state and this is down regulated by inhaled
glucocorticoids. In fact, treatment with inhaled glucocor-
ticoids reduces the expression of the activation markers
CD25 and HLA-DR in both CD4+ and CD8+ T-cell sub-
sets in peripheral blood of patients with asthma. In addi-Page 2 of 29
(page number not for citation purposes)
Journal of Occupational Medicine and Toxicology 2008, 3(Suppl 1):S6 http://www.occup-med.com/content/3/S1/S6tion, there is correlation between the down regulation of
CD4 and CD8 T-lymphocyte activation and the improve-
ment in asthma control. Treatment with inhaled glucocor-
ticoids reduces the number of activated T lymphocytes
(CD25+ and HLA-DR+) in the BAL from asthmatic
patients [7,8]. However, severe glucocorticoid-dependent
and resistant asthma is associated with persistent airway
T-lymphocyte activation [9-11].
In general, glucocorticoids substantially reduce the mast
cell/eosinophil/lymphocyte driven processes, while leav-
ing behind or even augmenting a neutrophil-mediated
process. Glucocorticoids enhance neutrophil function
through increased leukotriene and superoxide produc-
tion, as well as inhibition of apoptosis. Glucocorticoids
have no effect on sputum neutrophil numbers in patients
with severe persistent asthma [9]. Part of the anti-inflam-
matory activity of glucocorticoids in asthma may also
involve reduction in macrophage and resident cell eicosa-
noid (leukotriene B4 and thromboxane B2) and cytokine
and chemokine (e.g. IL-1β, IL-4, IL-5, IL-8, GM-CSF, TNF-
α, CCL3 [macrophage inflammatory protein-1alpha
(MIP-1α)] and CCL5 (RANTES) synthesis [7,12]. In addi-
tion to their suppressive effects on inflammatory cells,
glucocorticoids may also inhibit plasma exudation and
mucus secretion in inflamed airways. However, glucocor-
ticoids have no effect on sputum concentrations of fibrin-
ogen. There is an increase in vascularity in the bronchial
mucosa of asthmatics and high doses of inhaled glucocor-
ticoids, may reduce airway wall vascularity in asthmatic
patients. Inhaled glucocorticoids also attenuate the
increased airway mucosal blood flow present in asthmatic
patients [7,8].
Many in vitro studies have indicated that glucocorticoids
may participate in guiding the differentiation of T lym-
phocytes toward the Th2 phenotype [13]. The immuno-
suppressive effect of glucocorticoids after organ
transplantation is mainly due to preferential blockade of
Th1 cytokine expression and promotion of a Th2
cytokine-secreting profile. Glucocorticoids, in vitro (a)
inhibit IL-12 secretion from monocyte-macrophages and
dendritic cells, (b) decrease IL-12 receptor 1- and 2-chain
expression, thereby inhibiting IL-12 signaling, and (c)
inhibit IL-12-induced STAT-4 (transcription factor that
drives Th1 differentiation) phosphorylation without
affecting STAT-6 (transcription factor that drives Th2 dif-
ferentiation) phosphorylation (d), and thereby deviate
the immune response predominantly toward the Th2
phenotype [8,12].
In stable asthmatics systemic glucocorticoid treatment
produces a small but significant decrease of 16% in blood
CD3+CD4+ and a 12% increase in natural killer(NK)-cell
frequency within 3 hours. In contrast, the CD3+CD8+ T-
cell number and activation marker remains unchanged
[14]. In vitro fluticasone inhibits IL-5 and IL-13 and
enhances IL-10 synthesis in allergen-stimulated periph-
eral blood CD4+ T cell cultures in a concentration-
dependent manner [15]. Similarly, salmeterol, but not
salbutamol, also inhibits IL-5 and IL-13 and enhances IL-
10 synthesis in the same cultures [15]. When used in com-
bination the two drugs demonstrated an additive effect on
this pattern of cytokine production [15] perhaps through
an effect on NFAT and AP-1 transcription factors [16].
Furthermore, in vitro, glucocorticoids inhibit proliferation
and IL-4 and IL-5 secretion by human allergen-specific
Th2 lymphocytes [17]. Both beclomethasone and flutica-
sone inhibit allergen-induced peripheral blood T-cell pro-
liferation and their expression of IL-5 and GM-CSF in
asthmatics [18].
Interestingly, the combination of fluticasone and salme-
terol significantly inhibits production of IFN-γ, but not
that of Th2 cytokines (IL-5 and IL-13) from PBMCs from
asthmatic subjects [19]. This is in contrast with the results
of an earlier study [20]. When rolipram, a phosphodieste-
rase 4 inhibitor, is added to the fluticasone-salmeterol
combination, this triple combination inhibits IL-13 pro-
duction by PBMCs from asthmatic patients [19].
In vitro fluticasone alone increases and salmeterol alone
does not affect peripheral blood T-cell apoptosis in either
normal or asthmatic subjects [21,22]. Their combination
significantly increases peripheral blood T-cell apoptosis in
comparison with fluticasone alone and it is also able to
reduce the expression of the phosphorylated inhibitory κB
alpha (IκBα), thus limiting nuclear factor κB (NF-κB) acti-
vation [22].
Effects of theophylline on Th2 cells in asthmatic 
airways
Theophylline has been used in the treatment of asthma
for many decades and is still used worldwide for the treat-
ment of asthma. Low dose theophylline has recently been
shown to have significant anti-inflammatory effects in the
airways of the asthmatic patients [23,24]. This is sup-
ported by a reduced infiltration of eosinophils and CD4+
lymphocytes into the airways of asthmatic patients after
allergen challenge subsequent to low doses of theophyl-
line [25,26]. Low doses of theophylline also have reduced
the number of CD4+ and CD8+ T lymphocytes and IL-4-
and IL-5-containing cells in bronchial biopsies of asth-
matic subjects [27,28]. In addition, in an uncontrolled
study, in asthmatic patients, regular treatment with low
doses of theohylline reduced sputum eosinophils and IL-
5 expression, but not sputum CD4+ T lymphocytes and
IFN-γ [29]. In patients with severe persistent asthma
treated with high-doses of inhaled glucocorticoids, with-Page 3 of 29
(page number not for citation purposes)
Journal of Occupational Medicine and Toxicology 2008, 3(Suppl 1):S6 http://www.occup-med.com/content/3/S1/S6drawal of theophylline results in increased numbers of
activated CD4+ cells and eosinophils in bronchial biop-
sies [30]. In vitro, low concentrations of theophylline (<25
nM) can inhibit the migration of T lymphocytes to chem-
otactic factors [31]. Furthermore, theophylline, at high
concentrations, has been shown to reduce IL-2 produc-
tion by T cells and IL-2-dependent T cell proliferation and
induces nonspecific suppressor activity in human periph-
eral blood lymphocytes [32].
In vitro, high concentrations of theophylline suppress
CD4+ expression of both Th1 and Th2, excluding IL-5,
cytokines probably via inhibition of phosphodiesterases
[33,34]. In an animal model of asthma, both low and
high doses of aminophylline are effective in preventing
late-phase bronchoconstriction, bronchial hyperrespon-
siveness, and airway inflammation. Furthermore, amino-
phylline decreases Th2-related cytokine mRNA expression
but increases Th1-related cytokines mRNA expression
[35].
Effects of leukotriene-receptor antagonists and 
synthesis-inhibitors on Th2 cells in asthmatic 
airways
Leukotriene-receptor antagonists (pranlukast, zafirlukast,
montelukast) and synthesis-inhibitors (zileuton) reduce
the severity of bronchial hyperresponsiveness in asthma.
In asthmatic patients, these agents can reduce sputum,
bronchial biopsy and peripheral blood eosinophilia
induced by experimental challenge with allergen, aspirin,
sulfur dioxide or leukotriene (LT)E4[3,36].
In vitro, the cysteinyl-leukotriene receptor antagonist
pranlukast can concentration-dependently inhibit the
release of Th2 cytokines (IL-3, IL-4, GM-CSF), but not of
the Th1 cytokine IL-2, from mite allergen-stimulated
PBMCs from asthmatic patients [37]. Also, in an animal
model of asthma, treatment with pranlukast reduces IL-5
but has no effect on IFN-γ production [38]. In contrast,
high-doses of montelukast reduce IL-4, IL-5 and IL-13 lev-
els in the lung and IL-4 and IL-5 expression in BAL [39].
In similar studies, montelukast decreases IL-4 mRNA
expression in the lungs while increasing IFN-γ mRNA
expression after allergen challenge [40]. Interestingly, the
treatment of children with allergic rhinitis with montelu-
kast induces a significant decrease of nasal lavage IL-4 and
IL-13 and a significant increase of IFN-γ levels [41].
Effects of β2-agonists on Th2 cells in asthmatic 
airways
Despite some positive in vivo studies, particularly with for-
moterol and more recently with salmeterol, the anti-
inflammatory effect of short- and long-acting inhaled β2-
agonists has not been convincingly demonstrated in asth-
matic airways [3,8]. Although, it was initially proposed
that the bronchodilating and symptom-relieving effects of
long-acting inhaled β2-agonists may potentially mask
increasing inflammation and delay awareness of worsen-
ing asthma, there is no evidence that long-acting inhaled
β2-agonists worsen exacerbations of asthma or the chronic
airway inflammation in asthma [3].
In vitro studies using resting and activated murine Th1 and
Th2 cells have shown that a detectable level of the β2AR is
expressed only on resting and activated Th1 cells, but not
Th2 cells [42,43]. Baseline levels of intracellular cAMP are
similar in both subsets, but β2-agonists induce an increase
in cAMP levels in Th1 cells only [43].
Human peripheral blood mononuclear cells when stimu-
lated in vitro with β2-agonists show decreased levels of
IFN-γ and increased levels of IL-4, IL-5, and IL-10, an
effect that is thought to be mediated by decreasing IL-12
production thereby suggesting that β2-agonists promote
Th2 cytokine production. β2-agonists are potent and selec-
tive inhibitors of LPS- and CD40-CD40L-stimulated IL-12
production by human macrophages and dendritic cells
[44]. In accord with their ability to suppress IL-12 produc-
tion, when β2-agonists are added to neonatal cord blood
T cells, they selectively inhibit the development of Th1
cells and enhance Th2 cell development [44]. However, in
other in vitro studies β2-agonists have been shown to
inhibit the secretion of IL-4 and IL-5 in T cell lines [45].
Regular treatment of patients with mild asthma with the
long-acting β2-agonist formoterol does not decrease the
number of IL-4 immunoreactive cells in their bronchial
mucosa [46].
Effects of cromoglycate and nedocromil on Th2 
cells in asthmatic airways
Cromoglycate (cromolyn) has been shown to inhibit the
IgE-mediated mediator release from human mast cells,
and to suppress the activation of, and mediator release
from, other inflammatory cells (macrophages, eosi-
nophils, monocytes). Prolonged treatment of asthmatic
patients with cromoglycate decreases the percentage of
blood, sputum and BAL eosinophils, suggesting a direct
anti-inflammatory effect in human asthmatic airways.
Cromoglycate has also been shown to inhibit chloride
channels in vitro [8].
Cromoglycate and nedocromil are both very well toler-
ated and still widely prescribed, in some countries, for the
treatment of asthma in children. However the majority of
controlled studies do not show any efficacy of these drugs
in the treatment of persistent asthma compared with pla-
cebo although they show some efficacy in exercise-
induced bronchoconstriction [8]. In vitro studies also sug-
gest that nedocromil can modulate the differentiation of
Th1/Th2 cells [47] however there is a complete absence ofPage 4 of 29
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drugs measuring the Th1/Th2 balance in the lower air-
ways.
Omalizumab
There is a complete absence of controlled clinical trials in
asthmatic patients using omalizumab measuring the Th1/
Th2 balance in the lower airways.
Effects of immunosuppressant drugs on Th2 cells 
in asthmatic airways
Methotrexate may have a small glucocorticoid sparing
effect in adults with asthma who are dependent on oral
glucocorticoids. However, the overall reduction in daily
steroid use is probably not large enough to reduce steroid-
induced adverse effects. This small potential to reduce the
impact of steroid side-effects is probably insufficient to
offset the adverse effects of methotrexate [2,48]. The
absence of an inhibitory effect of methotrexate on a
number of inflammatory cells in the blood and mucosa of
the asthmatic patients suggests that the steroid-sparing
effect of methotrexate is achieved by modulating cell func-
tion rather than cell number [8]. Cyclosporin A inhibits
the allergen-induced late asthmatic reaction, the allergen-
induced increase in IL-5 and GM-CSF in mRNA+ cells in
BAL, and in the number of eosinophils in blood and
bronchial mucosa, but not the early asthmatic reaction
[8]. In vitro cyclosporin A inhibit allergen-driven T-cell
proliferation, production of IL-2, IL-4, and IL-5 by human
CD4+ helper T cells, and IL-5 production in PBMCs from
allergen-sensitized atopic asthmatic individuals at physio-
logic concentrations. In vitro cyclosporin A, at putative
therapeutic concentrations, has antiproliferative effects,
with equivalent potency, on T-lymphocytes from gluco-
corticoid-sensitive and -resistant asthmatics but in vitro T-
lymphocyte proliferation assays are not predictive of clin-
ical response to cyclosporin therapy in chronic severe
asthma [8,49].
In summary, the glucocorticoid sparing effect of
cyclosporin A is small and of questionable clinical signif-
icance. Given the side effects of cyclosporin A, the availa-
ble evidence does not recommend routine use of this drug
in the treatment of oral glucocorticoid-dependent asthma
[2,8,50].
New drugs which can potentially interfere with 
Th2 cells in asthmatic airways
Many new drugs are now in development for the treat-
ment of asthma. There has been an intensive search for
anti-inflammatory treatments for bronchial asthma that
are as effective as glucocorticoids but with fewer side
effects. Whereas one approach is to seek glucocorticoids
with a greater therapeutic index, other approaches involve
developing different classes of anti-inflammatory drugs
[51]. There is also a need for new treatments to deal with
the small minority of patients with more severe asthma
that is currently not well controlled by high doses of
inhaled glucocorticoids and a need for a safe oral drug
that would be effective in all atopic diseases (including
asthma, allergic rhinitis and atopic dermatitis), as they
often occur together [51].
Selective inhibition of Th2 lymphocytes function may be
effective and well tolerated and there are active research
programmes for such drugs in most pharmaceutical com-
panies [52].
Selective inhibitors of phosphodiesterase 4
A promising class of novel anti-inflammatory treatments
for asthma are the selective inhibitors of phosphodieste-
rase 4 (PDE4). PDE4 is expressed in macrophages, neu-
trophils, T cells and airway smooth muscle cells [8]. These
compounds inhibit the hydrolysis of intracellular cAMP,
which may result in bronchodilation and suppression of
inflammation. There are many compounds in this new
class of drugs in clinical development; however most of
the clinical studies reported have been performed with
cilomilast and roflumilast [8]. There are controlled clini-
cal trials suggesting some efficacy of roflumilast in mild to
moderate asthma and to prevent exercise-induced asthma
in adults [53]. However, the development of cilomilast as
an antiasthma drug has apparently been suspended.
There are no significant differences in the expression of
PDE4A, PDE4B and PDE4D in peripheral blood CD4 and
CD8 lymphocytes from normal and asthmatic patients
[54]. PDE4 subtype expression is lower and shows more
intersubject variability in CD8+ cells however [54]. Fur-
thermore, in vitro, Th1 lymphocytes show a reduced
expression of PDE4C isoform and a lack of PDE4D iso-
form compared to Th2 lymphocytes [55].
Cyclic adenosine monophosphate (cAMP) is a negative
regulator of T-cell activation. However, the effects of
cAMP on signaling pathways that regulate cytokine pro-
duction and cell cycle progression in Th1 and Th2 lym-
phocytes remain controversial.
In vitro, using allergen-induced human Th1 and Th2
clones both Th1 and Th2 cytokines production are equally
inhibited by selective PDE4 inhibitors [55]. However, the
increase in intracellular cAMP is significantly more in Th2
compared with Th1 clones [55]. In vitro, selective PDE4
inhibitors inhibit proliferation and IL-4 and IL-5 secretion
by human allergen-specific Th2 lymphocytes and Th1 and
Th2 clones [34,56]. Other in vitro studies suggest that
PDE4 inhibitors have complex inhibitory effects on Th1-
mediated immunity at the concentration ranges achieva-
ble in vivo, whereas Th2-mediated responses are mostlyPage 5 of 29
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developing immune response is explained by the effects of
PDE inhibitors on several factors contributing to T cell
priming: the cytokine milieu; the type of costimulatory
signal, i.e., up-regulation of CD86 and down-regulation
of CD80; and the antigen avidity [57].
In animal studies, PDE4 inhibitors inhibit antigen-medi-
ated T cell proliferation and skew the T cell cytokine pro-
file toward a Th2 phenotype by downregulating the
expression or production of Th1 cytokines without affect-
ing Th2 cytokine expression [58,59].
There is a complete absence of controlled clinical trials in
asthmatic patients using these drugs measuring the Th1/
Th2 balance in the lower airways.
Chemokine receptors antagonists targeting Th2 
cells in asthmatic airways
Numerous antibodies, receptor blocking mutant chemok-
ines and small molecules are now being evaluated for the
treatment of asthma. Chemokines have proven to be ame-
nable drug targets for the development of low molecular
weight antagonists by the pharmaceutical industry. CCR3,
CCR4, CCR8, and CRTH2 non-peptide antagonists are
involved in the recruitment and/or activation of Th2 cells
in the lung and are now being evaluated for the treatment
of bronchial asthma but so far, no clinical data for these
compounds have been reported. However, over the next
few years it is expected that many studies will have been
published at which time the potential of these exciting
new targets will be fully realized [60,61].
CCR3 antagonists and asthma
A range of low molecular weight chemicals have been
developed to antagonise CCR3, with the aim of selectively
inhibiting eosinophil recruitment into tissue sites. How-
ever, the results of recent clinical trials with monoclonal
antibodies directed against IL-5 question the role of eosi-
nophils in mediating the symptoms of asthma [62]. For
this reason, the plans for clinical development of many
CCR3 antagonists in asthma have been put on hold [63].
More recently novel oral CCR3 selective antagonists have
been developed by many pharmaceutical companies
including Brystol-Myers Squibb, GSK and Yamanouchi
Pharmaceuticals [64-71], including double CCR3 and H1
receptor antagonists [72]. Some of these compounds are
now undergoing clinical trials in asthma.
These compounds are able to prevent the activation and
recruitment of eosinophils, but not lymphocytes, in ani-
mal models of asthma [66,71,73]. However, in another
animal model of asthma, a CCR3 antagonist did not
decrease the number of eosinophils in lung tissues but
only antigen-induced clustering of eosinophils along the
airway nerves [74]. Immunostaining shows eotaxin in air-
way nerves and in cultured airway parasympathetic neu-
rons [74]. In vitro both IL-4 and IL-13 increase expression
of eotaxin in airway parasympathetic neurons [74]. Thus,
signaling via CCR3 mediates eosinophil recruitment to
airway nerves and may be a prerequisite to blockade of
inhibitory muscarinic M2 receptors by eosinophil major
basic protein [74].
N-nonanoyl (NNY)-CCL14[10-74] (NNY-CCL14) is an
N-terminally truncated and modified peptide derived
from the chemokine CCL14 that in vitro inhibits the activ-
ity of CCR3 on human eosinophils, because it is able to
induce internalization of CCR3 and to desensitize CCR3-
mediated intracellular calcium release and chemotaxis. In
contrast to naturally occurring CCL11, NNY-CCL14 is
resistant to degradation by CD26/dipeptidyl peptidase IV
(DP4). This compound is effective in animal models of
asthma [75]. N-Nonanoyl-CCL11 (NNY-CCL11) repre-
sents another similar compound with dual activity
restricted to CCR3 and CCR5. It also has receptor-inacti-
vating capacity and stability against DP4 degradation
[76]. All these new compounds have been developed by
Ipf Pharmaceuticals (http://www.ipf-pharmaceuticals.de/
index2.html).
Specific targeting of inhibitory receptors on CCR3+ cells
may be an alternative approach. For example cross-linking
of inhibitory receptor protein 60 (IR-p60)/CD300a inhib-
its mast cell and eosinophil activation and co-aggregation
of CD300a with CCR3 using a bi-specific antibody frag-
ment (LC1) has been shown to be effective in an animal
model of asthma [77], but is still untested in human
asthma.
TPIASM8 is a new inhaled compound consisting of two
modified RNA-targeting oligonucleotides directed against
the CCR3 receptor, and the common β subunit for the
receptors of IL-3, 5 and GM-CSF. TPIASM8 is currently in
phase II clinical development for the treatment of asthma
(http://www.topigen.com). This novel approach is
expected to have advantages over single mediator antago-
nists.
CCR4 antagonists and asthma
The utility of developing CCR4 antagonists is controver-
sial because CCR4-deficient mice do not show any change
in cell recruitment in the lung or induction of airway
hyperresponsiveness [78]. However many CCR4 antago-
nists are now in preclinical development and have been
shown to be effective in reducing the chemotaxis of Th2
cells in vitro and lung eosinophilic inflammation in an
animal model of asthma [79-84]. There are no published
controlled clinical trials of these compounds in asthma.Page 6 of 29
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The in vivo role of the CCL1/CCR8 axis in Th2-mediated
inflammation is far from clear. CCR8-deficient mice have
a marked reduction of airway eosinophil infiltration and
allergen-induced airway hyperresponsiveness, but the
CCR8 is not essential for the development of airway
inflammation in other animal models of asthma [85,86].
Overall these data, whilst highlighting a potential major
role for CCR8, suggest that multiple chemokines and
chemokine receptors may have redundant functions in
the pathogenesis of bronchial asthma. CCR8 and CCL1,
the CCR8 ligand, antagonists have been recently devel-
oped [87-90]. There are no published controlled clinical
trials of these compounds in asthma.
CRTH2 antagonists and asthma
Ramatroban (Baynas, BAY u3405), an orally active, trom-
boxan (Tx)A2 antagonist marketed in Japan for the treat-
ment of allergic rhinitis, is also an antagonist for CRTH2,
and in vitro inhibits PGD2-induced migration of eosi-
nophils. Ramatroban has been shown to partially attenu-
ate prostaglandin PGD2-induced bronchial
hyperresponsiveness in humans, as well as reduce anti-
gen-induced early- and late-phase inflammatory
responses in animal models of asthma [91].
A new selective CRTH2 antagonist named TM30089 is
structurally closely related to ramatroban but with less
affinity for TP and many other receptors including the
related anaphylatoxin C3a and C5a receptors, selected
chemokine receptors and the cyclooxygenase isoforms 1
and 2, attenuates airway eosinophilia and mucus cell-
hyperplasia in an animal model of asthma [92].
Many novel selective orally active CRTH2 antagonists
have been recently developed [93-99], but there are no
published studies on the effect of CRTH2 antagonists in
asthmatic patients, the results of the ongoing clinical trials
are awaited with interest [97]. A once day oral molecule
ODC9101 is now in phase IIa clinical trials in asthma
(http://www.oxagen.co.uk).
CCR5 agonists and asthma
Aminooxypentane (AOP)-RANTES/CCL5 is a full agonist
of human CCR5 [100] a chemokine receptor expressed
selectively on human Th1 lymphocytes. In an animal
model of asthma AOP-RANTES/CCL5 decreases allergen-
induced airway inflammation suggesting that targeting
CCR5 may also be effective [100].
Sphingosine 1-phosphate receptor agonists
Sphingosine 1-phosphate (S1P) in blood, lymph, and
immune tissues stimulates and regulates T cell migration
through their S1P(1) (endothelial differentiation gene
encoded receptor-1) G protein-coupled receptors
(S1P1Rs). S1P1Rs also mediate suppression of T cell pro-
liferation and cytokine production. In fact S1P decreases
CD4 T cell generation of IFN-γ and IL-4 [101].
The novel oral immunomodulator FTY720 is a chemical
derivative of myriocin, a metabolite of the ascomycete
Isaria sinclairii. The drug has recently been shown to be
effective in human kidney transplantation. In contrast to
classical immunosuppressants such as cyclosporine A or
FK506, FTY720 selectively and reversibly sequesters lym-
phocytes but not monocytes or granulocytes from blood
and spleen into secondary lymphoid organs, thereby pre-
venting their migration toward sites of inflammation and
allograft rejection. Moreover, FTY720 does not impair T
cell activation, expansion, and memory to systemic viral
infections or induce T cell apoptosis at clinically relevant
concentrations [102]. FTY720 is a structural analog of
sphingosine and following in vivo phosphorylation acts as
a agonist at S1P1Rs to block cell motility [102]. This leads
to sequestration of lymphocytes in secondary lymphatic
tissues and thus away from inflammatory lesions. Both
Th1 and Th2 cells express a similar pattern of FTY720-tar-
geted S1P1Rs. The inhibitory effect of FTY720 on airway
inflammation, airway hyperresponsiveness, and goblet
cell hyperplasia in an animal model of asthma, suggests a
potential role of this compound in the treatment of
asthma [102]. The accompanying lymphopenia could be
a serious side effect that would preclude the use of oral
FTY720 as an antiasthmatic drug [103].
However, in an animal model of asthma inhalation of
FTY720 prior to or during ongoing allergen challenge sup-
presses Th2-dependent eosinophilic airway inflammation
and bronchial hyperresponsiveness without causing lym-
phopenia and T cell retention in the lymph nodes [103].
Local treatment with FTY720 inhibits migration of lung
dendritic cells to the mediastinal lymph nodes, which in
turn inhibited the formation of allergen-specific Th2 cells
in lymph nodes. Also, FTY720-treated dendritic cells are
less potent in activating naive and effector Th2 cells [103].
Ca2+ release-activated Ca2+ channels blockers 
and asthma
The pyrazole derivative, YM-58483 (BTP2; http://
www.astellas.com), potently inhibits Ca2+ release-acti-
vated Ca2+ (CRAC) channels and IL-2 production in T
cells and IL-4 and IL-5 production in stimulated murine
Th2 cells, and IL-5 production in stimulated human
whole blood cells. YM-58483 inhibited airway eosinophil
infiltration, IL-4 and cysteinyl-leukotrienes content and
late phase asthmatic bronchoconstriction in animal mod-
els of asthma [104]. There are no published studies on
human asthma using CRAC channel inhibitors.Page 7 of 29
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Asthma is characterized by an increased expression of
components of the inflammatory cascade. These inflam-
matory proteins include cytokines, chemokines, growth
factors, enzymes, receptors and adhesion molecules. The
increased expression of these proteins seen in asthma is
the result of enhanced gene transcription since many of
the genes are not expressed in normal cells but are
induced in a cell-specific manner during the inflamma-
tory process. Changes in gene transcription are regulated
by transcription factors, which are proteins that bind to
DNA and modulate the transcriptional apparatus. Tran-
scription factors may therefore play a key role in the
pathogenesis of asthma [105,106].
Many transcription factors (for example NF-κB, AP-1,
GATA-3, STAT-1 STAT-6, c-Maf, NFATs and SOCS) have
been implicated in the differentiation of Th2 lymphocytes
and therefore represent therapeutic targets for asthma.
Several new compounds based on interacting with specific
transcription factors or their activation pathways are now
in development for the treatment of asthma and some
drugs already in clinical use (such as glucocorticoids)
work via transcription factors ([7]. One concern about this
approach is the specificity of such drugs, but it is clear that
transcription factors have selective effects on the expres-
sion of certain genes and this may make it possible to be
more selective [105,106]. In addition, there are cell spe-
cific transcription factors that may be targeted for inhibi-
tion, which could provide selectivity of drug action. One
such example is GATA-3, which has been reported to have
a restricted cellular distribution. In asthma it may be pos-
sible to target drugs to the airways by inhalation, as is cur-
rently utilised for inhaled glucocorticoids to avoid, or
minimize, any systemic effects [105,106].
NF-κB and AP-1
Transcription factors, such as nuclear factor (NF)-κB and
activator protein (AP)-1, play an important role in the
orchestration of the airway inflammation in asthma. The
role of NF-κB and AP-1 should be seen as an amplifying
and perpetuating mechanism that will exaggerate the dis-
ease-specific inflammatory process. In vitro, AP-1 and NF-
κB are also important for the function of Th2 cells
[105,106]. There is evidence for activation of both NF-κB
and AP-1 in the bronchial epithelial cells of patients with
asthma [105,106]. There are several possible approaches
to the inhibition of NF-κB. The most promising approach
might be the inhibition of IKKβ by small-molecule inhib-
itors, which are now in development by several compa-
nies [105-108]. Alternative strategies involve the
development of small peptide inhibitors of IKKβ/IKKγ
association. Interestingly, in animals NF-κB decoy oligo-
deoxynucleotides prevent and treat oxazolone-colitis and
thus affect a Th2-mediated inflammatory process [109].
One concern about the long-term inhibition of NF-κB is
that effective inhibitors may cause side effects, such as
increased susceptibility to infections, as mice that lack NF-
κB genes succumb to septicaemia [105-108].
A small-molecule inhibitor, PNRI-299, that targeting the
oxidoreductase redox effector factor-1, selectively inhibits
AP-1 transcription, without affecting NF-κB transcription,
significantly reduces airway eosinophil infiltration,
mucus hypersecretion, edema, and lung IL-4 levels in a
mouse asthma model [110]. In an animal model of
asthma intratracheally delivered AP-1 decoy oligodeoxy-
nucleotides attenuate eosinophilic airway inflammation,
airway hyperresponsiveness, mucous cell hyperplasia,
production of allergen-specific immunoglobulins, and
synthesis of IL-4, IL-5, and IL-13 in the lung [111].
GATA-3
The transcription factor GATA-3 seems to be of particular
importance in the differentiation of human Th2 cells and
its expression is increased in the peripheral venous blood
T cells from atopic asthmatics [106] and in bronchial
biopsies of stable asthmatics compared to controls and in
BAL cells of asthmatics after allergen challenge [112,113].
Many studies indicate a critical role for GATA-3 in the
development of airway eosinophilia, mucus hypersecre-
tion and airway hyperesponsiveness in animal models of
asthma [114] and suggest that local delivery of GATA-3
antisense oligonucleotides may be a novel approach for
the treatment of asthma [115]. This approach has the
potential advantage of suppressing the expression of vari-
ous proinflammatory Th2 cytokines simultaneously
rather than suppressing the activity of a single cytokine.
STAT1 blockers and asthma
The intracellular signaling intermediate signal transducer
and activator of transcription (STAT)1 mediates many
effects of IFN-γ and is implicated in the activation of T-bet,
a master regulator of Th1 differentiation. In animal mod-
els Th1 and Th2 cell trafficking is differentially controlled
in vivo by STAT1 and STAT6, respectively. STAT6, which
regulates Th2 cell trafficking, had no effect on the traffick-
ing of Th1 cells and STAT1 deficiency does not alter Th2
cell trafficking [116]. STAT1 in peripheral tissue regulates
the homing of antigen-specific Th1 cells through the
induction of a distinct subset of chemokines (CXCL9,
CXCL10, CXCL11, and CXCL16) [116]. CXCL10 replace-
ment partially restored Th1 cell trafficking in STAT1-defi-
cient mice in vivo, and deficiency in CXCR3, the receptor
for CXCL9, CXCL10, and CXCL11, impaired the traffick-
ing of Th1 cells [116]. Page 8 of 29
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bronchial epithelial cells in some, but not all [117], stud-
ies [118]. This has led to the development of decoy oligo-
nucleotides designed to block STAT1 activity. In an
animal model of asthma a single application of this
STAT1 decoy oligonucleotides significantly reduces air-
way hyperresponsiveness, the number of BAL eosinophils
and lymphocytes and the BAL level of IL-5 [119]. This
decoy oligonucleotides designated AVT-01 is currently
undergoing phase II studies in asthmatic patients (http://
www.avontec.de).
STAT-6
STAT6-knockout animals do not express Th2-type chem-
okines in the lung and as a result do not recruit allergen-
specific Th2 cells into the lung following allergen chal-
lenge [120]. Furthermore, STAT6-knockout animals fail to
develop goblet cell metaplasia in response to IL-13 instil-
lation, and this response can be rescued by epithelial-
directed expression of a STAT-6 transgene [121]. Previous
data investigating the localisation of STAT6 in the airways
of man has produced divergent results. In two studies
STAT-6 is present only within infiltrating cells of the nose
and bronchial mucosa [122,123], whilst in another two
studies STAT-6 is expressed predominantly within the
bronchial epithelium of mild asthmatic subjects
[124,125]. Therefore, although tempting as a target, a
clear rationale for targeting STAT-6 in asthma is not cur-
rently available. In vitro a STAT6 selective antisense signif-
icantly reduces eotaxin release from human airway
smooth muscle stimulated by IL-13 or IL-4 [126]. Interest-
ingly, in an animal model of asthma niflumic acid, a rela-
tively specific blocker of calcium-activated chloride
channel, inhibits IL-13-induced goblet cell hyperplasia,
MUC5AC expression, airway hyperresponsiveness, BAL
eosinophilia and eotaxin increase. Niflumic acid also
inhibits STAT6 activation and eotaxin expression in bron-
chial epithelial cells in vitro [127].
The adipocyte/macrophage fatty acid–binding protein
(FABP) aP2 is expressed in bronchial epithelial cells and it
is strongly upregulated by both IL-4 and IL-13 in a STAT6-
dependent manner. The presence of functional aP2 has
been shown very important in an animal model of asthma
[128].
c-maf
The effects of c-MAF appear to be fairly selective, since in
vitro studies have demonstrated that this factor is critical
for the production of IL-4, but not for IL-5 or IL-13
[129,130]. c-Maf expression in T lymphocytes is regulated
by IL-4 levels during Th differentiation. ICOS costimula-
tion potentiates the TCR-mediated initial IL-4 production,
possibly through the enhancement of NFATc1 expression
[131]. In animals c-maf is a Th2 cell-specific transcription
factor, which promotes the differentiation of Th2 cells
mainly by an IL-4-dependent mechanism [132]. c-maf-
transgenic mice produce higher serum levels of IgE and
IgG1, and their Th cells spontaneously developed into
Th2 cells in vitro[133]. In contrast, c-maf-deficient (c-maf
-/-) Th cells are unable to differentiate into Th2 cells in the
absence of exogenous IL-4. Although c-maf -/-Th2 cells,
differentiated in the presence of exogenous IL-4, produced
normal levels of IL-5, IL-10, and IL-13, the production of
IL-4 is severely impaired [129]. Furthermore, c-maf, inde-
pendent of IL-4, is also essential for normal induction of
CD25 (IL-2Rα chain) in developing Th2 cells, which
express higher levels than seen in Th1 cells. Blockade of
IL-2R signaling selectively inhibits the production of Th2
cytokines, but not IFN-γ or IL-2 [132]. An increased
number of c-maf immunoreactive cells have been
observed within the sputum and bronchial biopsies of
asthmatic patients compared with control subjects
[122,134]. There are no published studies on the effect of
selective c-maf inhibitors in vitro and/or in vivo.
NFATs
Nuclear factor of activated T cells (NFAT) was originally
described as a T-cell-specific transcription factor, which is
expressed in activated, but not resting T cells and is
required for IL-2 gene transcription. However, we now
know that NFAT is not T cell specific but is also expressed
in many other types of cells (e.g. mast cells, monocytes,
macrophages, eosinophils, epithelial cells, smooth mus-
cle and endothelial cells) [135,136].
The NFAT family of transcription factors include the cyto-
plasmic NFAT transcription factors [NFATc1 (NFATc),
NFATc2 (NFATp), NFATc3 (NFAT4, NFATx), NFATc4
(NFAT3), NFATc5] and nuclear NFAT (NFATn). NFATc
proteins are localised in the cytoplasm and activated by
stimulation of receptors coupled to calcium mobilisation.
Receptor stimulation and calcium mobilisation result in
activation of many intracellular enzymes, including the
calcium and calmodulin dependent phosphatase cal-
cineurin, a major upstream regulator of NFATc proteins.
Stimuli that elicit calcium mobilisation result in the rapid
dephosphorylation of NFATc proteins and their transloca-
tion to the nucleus where they have strong binding affin-
ity to DNA [137,138].
NFATs are ubiquitous regulators of cell differentiation
and adaptation [135] but in stimulated T cells NFATs are
mainly involved in the regulation of proliferation and
Th1/Th2 cytokine production [139,140]. For instance the
GM-CSF enhancer contains four composite NFATs/AP-1
DNA binding sites, three of which demonstrate coopera-
tive binding of NFATs and AP-1. The fourth site binds
NFATs and AP-1 independently. NFATs show a character-
istic ability to interact with AP-1 and NF-κB DNA bindingPage 9 of 29
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NFAT:AP-1 is more stable and has higher affinity for DNA.
Interestingly, preferential activation of NFATc1 correlates
with mouse strain susceptibility to allergic responses and
IL-4 gene expression [141]. NFATc2 appears to be impor-
tant for the activation of the Th2 cells [142-147]. In con-
trast, NFATc3 seems to enhances the expression of the Th1
cytokine genes, IFN-γ and TNF-α, and to suppress Th2
cytokine genes such as IL-4 and IL-5 in Th2 cells
[148,149].
As substrates for calcineurin, NFATs proteins are major
targets of the immunosuppressive drugs cyclosporin A
(see above) and FK506 because of their ability to inhibit
dephosphorylation of NFATs. Bis(trifluoromethyl)pyra-
zoles (BTPs) are novel inhibitors of both Th1 and Th2
cytokines production [150,151]. Identified initially as
inhibitors of IL-2 synthesis, BTPs inhibit IL-2 production
with a 10-fold enhancement over cyclosporin A. Addi-
tionally, the BTPs show inhibition of IL-4, IL-5, IL-8, and
CCL11 production [150,151]. Unlike the IL-2 inhibitors,
cyclosporin A and FK506, the BTPs do not directly inhibit
the dephosphorylation of NFAT by calcineurin. There are
no published studies on NFATc1 inhibitors in asthma.
SOCS modulation of Th1/Th2 differentiation
Suppressors of cytokine signaling (SOCS)-1 interacts
directly with the Janus kinases (JAK) and inhibits their
tyrosine-kinase activity [152]. SOCS1 is an important in
vivo inhibitor of type I interferon signaling [153]. A
SOCS1 promoter polymorphism (-1478CA>del) is associ-
ated with adult asthma [153]. In vitro this SNPs enhances
the transcription of SOCS1 in human lung epithelial cells,
but reduces phosphorylation of STAT1 stimulated with
IFN-β [153]. SOCS-3 is predominantly expressed in Th2
cells and inhibits Th1 differentiation [154]. SOCS3 also
has a role in Th3 differentiation [155,156]. SOCS-3 trans-
genic mice shows increased Th2 responses and an asthma-
like phenotype. In contrast, SOCS-3 knockout mice, has
decreased Th2 development [157]. These data suggest that
SOCS-3 may be a new target for the development of anti-
asthma drugs [156]. It has been suggested that enhance-
ment of the expression of SOCS-5 in CD4+ T cells might
be a useful therapeutic approach to Th2-dominant dis-
eases [158]. In fact, transfer of primed CD4+ T cells consti-
tutively expressing SOCS-5 along with eye drop challenges
in a murine allergic conjunctivitis model resulted in atten-
uated eosinophilic inflammation with enhanced IFN-γ
and decreased IL-13 production [159]. However, it should
be noted that SOCS-5 appears to be dispensable for the
development of Th1 responses in vivo, as demonstrated by
use of the SOCS-5 knockout mice [160]. SOCS-5-deficient
CD4+ T cells can differentiate into either Th1 or Th2 cells
with the same efficiency [160]. These data have been con-
firmed, in an animal model of asthma where significantly
more eosinophils in the airways and higher BAL levels of
IL-5 and IL-13 were observed in the SOCS-5 transgenic
than the wild-type mice. Airway hyperresponsiveness in
the asthma model of SOCS-5 transgenic was also
enhanced compared to wild-type mice. Ovalbumin-stim-
ulated CD4+ T cells from the primed SOCS-5 transgenic
mice produced significantly more IL-5 and IL-13 than
CD4+ T cells from wild-type mice [161]. This finding
raises questions about the therapeutic utility of using
enhancement of SOCS-5 expression for Th2-mediated dis-
eases, such as asthma.
Peroxisome proliferator-activated receptors
Peroxisome proliferator-activated receptors (PPARs) are
transcription factors belonging to the nuclear receptor
superfamily. PPARs are activated by an array of polyunsat-
urated fatty acid derivatives, oxidized fatty acids, and
phospholipids and are proposed to be important modu-
lators of allergic inflammatory responses [162]. The three
known PPAR subtypes α, γ and δ, show different tissue
distributions and are associated with selective ligands.
PPARs are expressed by eosinophils, T-lymphocytes and
alveolar macrophages, as well as by epithelial, and
smooth muscle cells. PPAR-α and -γ are expressed in eosi-
nophils and their activation inhibits in vitro chemotaxis
and antibody-dependent cellular cytotoxicity [163].
PPAR-α and -γ are both expressed in monocytes/macro-
phages. PPAR-γ is expressed in eosinophils and T lym-
phocytes. In vivo, inflammation induced by leukotriene B4
(LTB4), a PPAR-α ligand, is prolonged in PPAR-α-deficient
mice, suggesting an anti-inflammatory role for this recep-
tor [164]. In contrast, in mice injected with lipopolysac-
charide (LPS), activation of PPAR-α induces a significant
increase in plasma tumour necrosis factor- (TNF-α) levels
[164].
PPAR-γ ligands significantly inhibit production of IL-5
from T cells activated in vitro[165]. In a murine model of
allergic asthma, mice treated orally with ciglitazone, a
potent synthetic PPAR-γ ligand, have significantly reduced
lung inflammation and mucous production following
induction of allergic asthma. T cells from these ciglitazone
treated mice also produce less IFN-γ, IL-4, and IL-2 upon
rechallenge in vitro with allergen [165].
Activation of PPAR-γ alters the maturation process of den-
dritic cells (DCs), the most potent antigen-presenting
cells. By targeting DCs, PPAR-γ activation may be involved
in the regulation of the pulmonary immune response to
allergens [162]. Using a model of sensitization, based on
the intratracheal transfer of ovalbumin-pulsed DCs, ros-
iglitazone, another selective PPAR-γ agonist, reduces the
proliferation of antigen-specific T cells in the draining
mediastinal lymph nodes but dramatically increases the
production of IL-10 by these T cells. After aerosol chal-Page 10 of 29
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reduced compared to control mice. Inhibition of IL-10
activity with anti-IL-10R antibodies partly restored the
inflammation [162,166].
PPAR-α and PPAR-γ ligands also decrease antigen-
induced airway hyperresponsiveness, lung inflammation
and eosinophilia, cytokine production, and GATA-3
expression as well as serum levels of antigen-specific IgE
in many different animal models of asthma [163,167-
170]. These studies suggest that PPAR-α and PPAR-γ
(co)agonists might be a potential anti-inflammatory treat-
ment for asthma [171-173]. Interestingly, in vitro theo-
phylline, procaterol and dexamethasone induce PPAR-γ
expression in human eosinophils [174,175].
MAP kinase inhibitors
There are three major mitogen-activated protein (MAP)
kinase pathways and there is increasing recognition that
these pathways are involved in the pathogenesis of
asthma.
p38 MAPK inhibitors
p38 MAPK kinase is a Ser/Thr kinase involved in many
processes thought to be important in lower airways
inflammatory responses and tissue remodeling. There is,
however, a paucity of reports specifically addressing the
role of p38 kinase in asthma [107,176].
There are four members of the p38 MAP kinase family and
they differ in their tissue distribution, regulation of kinase
activation and subsequent phosphorylation of down-
stream substrates. They also differ in terms of their sensi-
tivities toward the p38 MAP kinase inhibitors [107,176].
In general, p38 MAPKs are activated by many stimuli,
including cytokines, hormones, ligands for G protein-
coupled receptors, and elevated levels of these cytokines
are associated with asthma. The synthesis of many inflam-
matory mediators such as TNFα, IL-4, IL-5, IL-8, RANTES
and eotaxins, thought to be important in asthma patho-
genesis, are regulated through activation of p38 MAPK.
p38 MAPK can affect the transcription of these genes but
also has major effects on mRNA stability. In addition, p38
MAPK appears to be involved in glucocorticoid-resistance
in asthma [107,176].
SB 203580, an early selective inhibitor of p38 MAP kinase,
inhibits the synthesis of many inflammatory cytokines,
chemokines and inflammatory enzymes. Interestingly, in
vitro SB203580 appears to have a preferential inhibitory
effect on synthesis of Th2 compared to Th1 cytokines,
indicating their potential application in the treatment of
asthma [177]. Inhaled p38α MAPK antisense oligonucle-
otide attenuates asthma in an animal model [178]. Sev-
eral oral and inhaled p38MAPK inhibitors are now in
clinical development [179]. Whether this new potential
class of anti-inflammatory drugs will be safe in long-term
studies in human asthma remains to be established. For
the successful use of MAPK inhibitors in clinical trial on
patients with asthma these compounds must be very spe-
cific to reduce the side-effects of the plethora of physiolog-
ical MAPK functions. However, options to improve safety
include inhaled delivery and use as a steroid-sparing
agent.
JNKs
The c-Jun NH2-terminal kinases (JNKs) phosphorylate
and activate members of the activator protein-1 (AP-1)
transcription factor family and other cellular factors
implicated in regulating altered gene expression, cellular
survival (apoptosis), differentiation and proliferation in
response to cytokines, growth factors and oxidative stress
and cancerogenesis. Since many of these are common
events associated with the pathogenesis of asthma, the
potential of JNK inhibitors as therapeutics has attracted
considerable interest. Furthermore, in patients with severe
glucocorticoid-resistant asthma there is increased expres-
sion of the components of the pro-inflammatory tran-
scription factor activator protein 1 (AP-1) and enhanced
JNK activity [11,180].
The c-jun N-terminal (JNK) group of MAPK consists of
three isoforms, encoded by three different genes, of which
the JNK1 and 2 isoforms are widely distributed, while
JNK3 is mainly located in neuronal tissue. Gene disrup-
tion studies in mice demonstrate that JNK is essential for
TNFα-stimulated c-Jun phosphorylation and AP-1 activ-
ity, and is also required for some forms of stress-induced
apoptosis. JNKs enhance the transcriptional activity of AP-
1 by phosphorylation of the AP-1 component c-Jun on
serine residues 63 and 73 and thereby increasing AP-1
association with the basal transcriptional complex. JNKs
may also enhance the activity of other transcription fac-
tors such as ATF-2, Elk-1 and Sap-1a. Many immune and
inflammatory genes including cytokines, growth factors,
cell surface receptors, cell adhesion molecules and pro-
teases such as matrix metalloprotease 1 (MMP-1) are reg-
ulated by AP-1 and ATF-2 presumably through the JNK
pathway. JNKs do not only affect transcription of cytokine
mRNAs but may also enhance the stability of some
mRNAs such as that for IL-2 and nitric oxide synthase 2
(NOS2) [107].
JNK activation may also be important in the regulation of
the immune response. JNK polarizes the differentiation of
CD4+ T cells to a Th1-type immune response by a tran-
scriptional mechanism involving the transcription factor
nuclear factor of activated T cells 1 (NFATc1). JNK1 and
JNK2 knockout mice have similar phenotypes but some
subtle differences exist e.g. JNK2(-/-) CD8+ cells showPage 11 of 29
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not expand [107].
SP600125 (Signal Pharmaceuticals/Celgene), a JNK
inhibitor, inhibited TNFα and IL-2 production in human
monocytes and Jurkat cells respectively and attenuated
TNFα- and IL-1β-induced GM-CSF, RANTES and IL-8 pro-
duction in primary human airway smooth muscle cells. In
addition, in an animal model of chronic asthma SP-
600125 (30mg/kg sc) reduces bronchoalveolar lavage
accumulation of eosinophils and lymphocytes, cytokine
release, serum IgE production and smooth muscle prolif-
eration after repeated allergen exposure. Similar results
were seen with the dual AP-1/NF-κB inhibitor SP100030
[181]. These data indicate that JNK inhibitors may be
effective in the treatment of asthma.
A more selective second generation JNK-selective inhibi-
tor [JNK-401(CC-401)] has successfully completed a
phase I, double-blind, placebo controlled, ascending sin-
gle intravenous dose study in healthy human volunteers
(http://www.celgene.com). Studies will examine whether
JNK-401 will be glucocorticoid sparing and lacking many
of the glucocorticoid side effects in humans.
The JNK pathway is implicated in a number of physiolog-
ical and pathological functions in a range of human dis-
eases. Due to the extensive cross-talk within this signalling
cascade, as well as its cell-type- and response-specific
modulation, it is difficult to predict potential adverse
events that might arise from pathway inhibition. How-
ever, the fact that JNK inhibitors are progressing in clinical
trials indicates that the utility of targeting this pathway for
therapeutic benefit in asthma and will probably be deter-
mined within the near future.
Heparin-like molecules
Glycosaminoglycans are large, polyanionic molecules
expressed throughout the body. The GAG heparin, co-
released with histamine, is synthesised by and stored
exclusively in mast cells, whereas the closely related mol-
ecule heparan sulphate is expressed, as part of a proteogly-
can, on cell surfaces and throughout tissue matrices [182].
An important feature of chemokines is their ability to
bind to the glycosaminoglycan side chains of proteogly-
cans, predominately heparin and heparan sulfate. To date,
all chemokines tested bind to immobilised heparin in
vitro, as well as cell surface heparan sulfate in vitro and in
vivo. These interactions play an important role in modu-
lating the action of chemokines by facilitating the forma-
tion of stable chemokine gradients within the vascular
endothelium and directing leukocyte migration, by pro-
tecting chemokines from proteolysis, by inducing chem-
okine oligomerisation, and by facilitating transcytosis
[183]. There are data suggesting a role for mast cell-
derived heparin in enhancing eotaxin-mediated eosi-
nophil recruitment thereby reinforcing Th2 polarisation
of inflammatory responses [183]. However, heparan sul-
fate has been shown in vitro to promote a Th1 response,
decreasing the production of IL-4 [184]. Heparin and
related molecules have been found to exert antiinflamma-
tory effects in vitro and in animal models of asthma and
that the antiinflammatory activities of heparin are dissoci-
able from its anticoagulant nature, suggesting that these
characteristics could yield novel antiinflammatory drugs
for asthma [185-187]. The inhalation of heparin prevents
exercise-induced bronchoconstriction [188-190]. A phase
II study in mild asthma using IVX 0142, a novel heparin-
derived oligosaccaride, has just been completed
(http:clinicaltrials.gov/ct/show/NCT00232999;jsessio
nid=25FE6BB25329EDD9E1860C6D5851921F?order=1.
Modulators of the synthesis or action of key 
proinflammatory Th2 cell cytokines
Over one hundred mediators have now been implicated
in asthmatic inflammation, including multiple cytokines,
chemokines and growth factors. Blocking a single media-
tor is therefore unlikely to be very effective in this complex
disease and mediator antagonists have so far not proved
to be very effective compared with drugs that have a broad
spectrum of anti-inflammatory effects, such as glucocorti-
coids [191]. The potential of blocking Th2 cytokines with
pro-inflammatory action such as of IL-4, IL-5 and IL-13
has still not been completely explored. Also, anti-inflam-
matory cytokines such as IL-10, IL-12, IL-18, IL-21, IL-23,
IL-27 and interferons may have a therapeutic potential in
asthma. TNF-α blockers may also be useful particularly in
severe asthma.
IL-4 blockers and asthma
IL-4 analogues that act as antagonists have been devel-
oped which fail to induce signal transduction and block
IL-4 effects in vitro. These IL-4 antagonists prevent the
development of asthma in vivo in animal models
[192,193].
However, the development of pascolizumab (SB
240683), a humanized anti-interleukin-4 antibody, as
well as of a blocking variant of human IL-4 (BAY36-1677)
has apparently been discontinued.
Soluble IL-4 receptors (sIL-4R) that act as IL-4R antago-
nists have also been developed [194], they are effective in
an animal model of asthma [195] and a single nebulised
dose of sIL-4R prevents the fall in lung function induced
by glucocorticoid withdrawal in moderate/severe asth-
matics [196]. Subsequent studies have shown that weekly
nebulisation of sIL-4R improves asthma control over 3
months [197]. However further studies in patients with
milder asthma proved disappointing and the clinicalPage 12 of 29
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ued.
In an animal model of asthma a IL-4Rα antisense oligonu-
cleotide (IL-4Rα ASO) specifically inhibits IL-4Rα protein
expression in lung after inhalation in allergen-challenged
mice [198]. Inhalation of IL-4Rα ASO attenuated allergen-
induced AHR, suppressed airway eosinophilia and neu-
trophilia, and inhibited production of airway Th2
cytokines and chemokines in previously allergen-primed
and -challenged mice [198]. Histological analysis of lungs
from these animals demonstrated reduced goblet cell
metaplasia and mucus staining that correlated with inhi-
bition of MUC5AC gene expression in lung tissue. These
data support the potential utility of a dual IL-4 and IL-13
oligonucleotide inhibitor in asthma, and suggest that
local inhibition of IL-4Rα in the lung is sufficient to sup-
press allergen-induced pulmonary inflammation and
AHR in mice [198].
A novel approach is represented by an IL-4 peptide-based
vaccine for blocking IL-4 on a persistent basis. Vaccinated
mice produces high titers of IgG to IL-4. Serum ovalbu-
min-specific IgE, eosinophil accumulation in BAL, goblet
cell hyperplasia, tissue inflammation and AHR are mark-
edly suppressed in vaccinated mice in an animal model of
asthma [199].
IL-13 blockers and asthma
Blocking IL-13, but not IL-4, in animal models of asthma
prevents the development of airway hyperresponsiveness
after allergen, despite a strong eosinophilic response
[121,200,201]. In addition, soluble IL-13Rα2 is effective
in blocking the actions of IL-13, including IgE production,
pulmonary eosinophilia and airway hyperresponsiveness
in animal models of asthma [202] and humanised IL-
13Rα2 is now entering phase I clinical trials in asthma
[203]. Also an anti-IL-13Rα1 antibody is in preclinical
development for the treatment of asthma (http://
www.zenyth.com).
A human anti human IL-13 IgG4 monoclonal antibody
(CAT-354) that blocks IL-13 effects in an animal model of
asthma [204] is in phase II clinical trials in severe asthma
(http://www.cambridgeantibody.com). In addition, Cen-
tocor (http://www.centocor.com) has developed an anti-
human IL-13 antibody that is effective in animal models
of asthma [201,205] and IMA-638 (IgG1, kappa), a
humanized antibody to human IL-13 from Wyeth
Research is effective in animal models of asthma
[202,206].
As for IL-4 (see above) a novel approach is represented by
an IL-13 peptide-based vaccine for blocking IL-13 on a
persistent basis. Vaccination significantly inhibits increase
in inflammatory cell number and IL-13 and IL-5 levels in
BAL. Serum total and ovalbumin-specific IgE are also sig-
nificantly inhibited. Moreover, allergen-induced goblet
cell hyperplasia, lung tissue inflammatory cell infiltration
and AHR are significantly suppressed in vaccinated mice
in an animal model of asthma [207].
IL-4 muteins indicate two types of IL-4 variants whose
tyrosine at 124 is replaced with aspartate (Y124D) and
arginine at 121 is replaced with aspartate (R121D/
Y124D). IL-4 muteins act as antagonists for both IL4 and
IL-13, because they are able to bind to IL-4R/IL13R, but
do not transduce the signal. Bayer initially developed
R121D/Y124D (pitrakinra, BY-16-9996, Aerovant) and
now the compound is in phase IIa clinical trial for the
treatment of asthma under license to Aerovance [203].
Promising results have been recently published on the
efficacy of this compound in the prevention of late phase
asthmatic responses on allergen challenge in asthmatics
[203].
Novel “traps” composed of fusions between two distinct
receptor components and a portion of the Fc region of the
antibody molecule, result in the generation of blockers
with markedly increased affinity over that offered by sin-
gle component reagents, dual IL-4/IL-13 trap is in preclin-
ical development for asthma (http://
www.regeneron.com).
IL-5
The Th2 cell cytokine, IL-5, plays an important role in
eosinophil maturation, differentiation, recruitment, and
survival. IL-5 knockout mice appeared to confirm a role in
asthma models where eosinophilia and AHR is markedly
suppressed. Humanised anti-IL-5 antibodies have been
developed and a single i.v. infusion of one of these
(mepolizumab) markedly reduces blood and sputum
eosinophilia for several months. Unfortunately, there was
no significant effect on the early or late response to aller-
gen challenge, base-line AHR or FEV1[62]. A similar study
in moderate/severe persistent asthma showed similar
results on eosinophilia but with no improvements in
symptoms or lung function [208]. In a subsequent study
eosinophil numbers within the bronchial mucosa were
only reduced by ∼50 by mepolizumab treatment but again
no effect on lung function was noted [209]. These data
have raised questions over the importance of eosinophils
in asthma. In a controlled clinical trial, administration of
mepolizumab, over a period of 6 months, to asthmatic
patients markedly reduces peripheral blood eosinophils
without altering the distribution of T-cell subsets and acti-
vation status (pattern of Th1 and Th2 cytokine produc-
tion) of blood lymphocytes [210].Page 13 of 29
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RNA, has been able to block IL-5Rα expression, decrease
bone marrow eosinophilopoiesis and blood and BAL
eosinophilia in an animal model of asthma showing new
potential blockers of IL-5 function [211,212]. These new
compounds have still not been tested in human asthma.
IL-6 antagonists and asthma
Interleukin-6 and related cytokines, interleukin-11, leuke-
mia inhibitory factor, oncostatin M, ciliary neurotrophic
factor, and cardiotrophin-1 are all pleiotropic and exhibit
overlapping biological functions. Functional receptor
complexes for the IL-6 family of cytokines share the signal
transducing component glycoprotein 130 (gp130).
Unlike cytokines sharing common β and common γ
chains that mainly function in hematopoietic and lym-
phoid cell systems, the IL-6 family of cytokines function
extensively outside these systems as well, owing to the
ubiquitous expression of gp130 [213].
The IL-6 receptor complex (IL-6R) consists of either the
membrane-bound IL-6 receptor (mIL-6R) or the soluble
IL-6 receptor (sIL-6R) complexed with gp130. There are
increased levels of sIL-6R in the airways of patients with
allergic asthma as compared to those in controls. In addi-
tion, local blockade of the sIL-6R in a murine model of
asthma led to suppression of Th2 cells in the lung [214].
By contrast, blockade of mIL-6R induced local expansion
of Foxp3-positive CD4+CD25+ Tregs with increased
immunosuppressive capacities. CD4+CD25+ but not
CD4+CD25- lung T cells selectively expressed the IL-6Rα
chain and showed IL-6-dependent STAT-3 phosphoryla-
tion. Finally, in an animal model of asthma CD4+CD25+
T cells isolated from anti-IL-6R antibody-treated mice
exhibited marked immunosuppressive and antiinflamma-
tory functions [214].
IL-9 antagonists and asthma
Numerous in vitro and in vivo studies in both animals and
patients with asthma have shown that IL-9 is an impor-
tant inflammatory mediator in asthma. IL-9 is produced
in the lung by a number of different cell types (Th2 lym-
phocytes, mast cells, eosinophils, bronchial epithelial
cells), and has multiple effects on a wide range of inflam-
matory and structural cells within the lung, including
bronchial epithelial and smooth muscle cells (release of
CCL11). IL-9 may be involved in IL-4-triggered IgE pro-
duction in vitro, mast cells and eosinophils recruitment
and activation to the lung, bronchial mucus cell hyperpla-
sia (and MUC4 induction), subepithelial deposition of
collagen, and airway hyperresponsiveness [215]. Animal
data indicate that IL-9 can promote asthma through IL-13-
independent pathways via expansion of mast cells, eosi-
nophils, and B cells, and through induction of IL-13 pro-
duction by hemopoietic cells for mucus production and
recruitment of eosinophils by lung epithelial cells [216].
IL-9 mRNA and protein is increased in the bronchial
mucosa of atopic asthmatics, where it is expressed pre-
dominantly in lymphocytes [217,218]. In addition, BAL
IL-9 levels are up-regulated in asthmatics following aller-
gen challenge [219].
In animal models of asthma the overexpression of IL-9
causes BAL eosinophilia, peribronchial accumulation of
collagen and increased BAL levels of CCL5 and CTGF
[220].
However, in Th2 cytokine-deficient mice (IL-4, IL-5, IL-9,
and IL-13; single to quadruple knockouts) IL-4 alone can
activate all Th2 effector functions even in the combined
absence of IL-5, IL-9, and IL-13 [221] and the Th2 pulmo-
nary inflammation is unchanged in IL-9-deficient mice,
despite a reduced number of lung mast cells and goblet
cells [222]. Despite this, in an animal model of asthma
the treatment with an anti-IL-9 antibody reduces airway
inflammation and hyperresponsiveness [223,224] sug-
gesting that blockade of IL-9 may be a new therapeutic
strategy for bronchial asthma [215]. Interestingly, after
allergen exposure an anti-IL-9 antibody significantly
reduces bone marrow eosinophilia in an animal model
primarily by decreasing newly produced and mature eosi-
nophils. Anti-IL-9 treatment also reduces blood neu-
trophil counts, but does not affect BAL neutrophils [225].
IL-10 modulation and asthma
New "counterregulatory" models of asthma pathogenesis
suggest that dysfunction of IL-10–related regulatory
mechanisms might underlie the development of asthma.
IL-10 is produced by several cell types, including mono-
cytes, macrophages, T lymphocytes, dendritic cells and
mast cells. IL-10 is a unique cytokine with a wide spec-
trum of anti-inflammatory effects. It inhibits the secretion
of TNFα and IL-8 from macrophages and tips the balance
in favour of antiproteases by increasing the expression of
endogenous tissue inhibitors of MMPs (TIMPS). Some of
the actions of IL-10 can be explained by an inhibitory
effect on NF-κB, but this does not account for all effects,
as IL-10 is very effective at inhibiting IL-5 transcription,
which is independent of NF-κB. In mice many effects of
IL-10 appear to be mediated by an inhibitory effect on
PDE-4, but this does not appear to be the case in human
cells [191].
However in animal models, IL-10, although inhibiting
lipopolysaccharide-induced airway inflammation, also
causes airway mucus metaplasia, inflammation, and
fibrosis. These responses are mediated by multiple mech-
anisms with airway mucus metaplasia being dependent
on the IL-13/IL-4Rα/STAT-6 activation pathway whereasPage 14 of 29
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way [226].
IL-10 concentrations are reduced in induced sputum from
patients with asthma or COPD, indicating that this might
be a mechanism for increasing lung inflammation in
these diseases. In addition, IL-10 production is decreased
in peripheral blood mononuclear cells of patients with
mild asthma and is further attenuated in severe persistent
asthma compared to mild asthma [227,228]. Patients
with severe persistent asthma have increased frequency of
a haplotype associated with low production of IL-10 by
the alveolar macrophages [229]. Furthermore, a defect in
glucocorticoid-induced IL-10 production has also been
described in blood T lymphocytes from patients with glu-
cocorticoid-resistant asthma [228].
The potent immunosuppressive and anti-inflammatory
action of IL-10 has suggested that it may be useful thera-
peutically in the treatment of asthma. Recombinant
human IL-10 has already been licensed for Crohn's dis-
ease and psoriasis by daily subcutaneous injection over 4
weeks and it is reasonably well tolerated causing only a
reversible dose-dependent anemia and thrombocytope-
nia. Another possibility for therapy in the future is the
development of other agonists for the IL-10 receptor, or
drugs that activate the unique, but so far unidentified, sig-
nal transduction pathways activated by this cytokine
[191].
Recent data also suggests that vitamin D3 in conjunction
with a glucocorticoid may restore the reduced expression
of Il-10 seen in T-cells from patients with severe asthma
[228].
IL-12 modulation and asthma
IL-12 is essential for the development of Th1 immune
response, leading to their production of IFN-γ. In addition
to priming CD4+ T cells for high IFN-γ production, IL-12
also contributes to their proliferation once they have dif-
ferentiated into Th1 cells. IL-12 is also capable of inhibit-
ing the Th2-driven allergen-induced airway changes in
mice and was therefore considered a new potential drug
for the treatment of asthma. In man, IL-12 production is
decreased in PBMCs, alveolar macrophages and bronchial
biopsies of patients with mild asthma and IL-12 synthesis
is further attenuated in PBMCs from severe persistent
asthma compared to mild asthma [227]. Inhalation of IL-
12 has been shown to inhibit allergic inflammation in
murine models while decreasing adverse effects seen with
systemic administration of this cytokine and adenoviral
IL-12 gene transduction may be effective in inducing IL-12
expression in the airways [230]. However, an initial study
of inhaled IL-12 in humans with asthma was terminated
because of adverse effects, including one death. Further-
more, the use of systemically administered IL-12 in
patients with asthma has been limited due to cytokine
toxicity and lack of clinical efficacy despite a significant
reduction in the number of blood and sputum eosi-
nophils [231]. Another treatment option that has the
potential of inducing a Th1 cytokine response is the use of
IL-12 linked to polyethylene glycol moieties. This mode
of administration is likely to enhance cytokine delivery to
the target organ, while decreasing its toxicity. Also intrana-
sal delivery of IL-12 may provide another approach for the
treatment of asthma [232].
IL-15
The IL-15 gene is located on chromosome 4q27, approxi-
mately distal to the IL2 gene and may be associated with
an increased susceptibility to asthma [233,234].
IL-15 shares many biologic activities with IL-2. Both
cytokines bind a specific α subunit, and they share the
same β and γ common receptor subunits for signal trans-
duction. IL-15, in the presence or absence of TNF-α,
reduces spontaneous apoptosis in human eosinophils.
The number of cells expressing IL-15 is significantly
increased in the bronchial mucosa from patients with
Th1-mediated chronic inflammatory diseases of the lung
such as sarcoidosis, tuberculosis, and COPD compared
with asthmatic patients and normal subjects [235]. The
expression of IL-15 is also increased in the bronchial
mucosa of asthmatic patients compared to normal sub-
jects.
In an animal model of asthma overexpression of IL-15
suppresses Th2-mediated-allergic airway response via
induction of CD8+ T cell-mediated Tc1 response [236].
However in another animal model of asthma blocking IL-
15 prevents the induction of allergen-specific T cells and
allergic airway inflammation [237]. Natural killer (NK)
cells are divided into NK1 and NK2 subsets and the ratio
of IL-4 + CD56 + NK2 cells in PBMCs of asthmatic
patients is higher than in healthy individuals [238].
STAT6 is also constitutively activated in NK2 clones from
asthmatic patients possibly as a result of IL-15 stimulating
their proliferation [238]. There are no clinical studies on
the effect of IL-15 pathway modulation in asthmatic
patients. Interestingly, a two weeks treatment with the
inhaled glucocorticoid fluticasone decreased the numbers
of IL-15+ cells in the bronchial mucosa of stable asthmat-
ics [239].
IL-18 modulation and asthma
IL-18, originally identified as an IFN-γ-inducing factor, is
a unique cytokine that enhances innate immunity and
both Th1- and Th2-driven immune responses. IL-18 is
able to induce IFN-γ, GM-CSF, TNFα and IL-1, to activate
killing by lymphocytes, and to up-regulate the expressionPage 15 of 29
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naive T cells to develop into Th2 cells. IL-18 also induces
IL-4 and/or IL-13 production by NK cells, mast cells and
basophils [240].
The same dualism is present in vivo after administration of
IL-18 in animal models of asthma. Vaccination with aller-
gen-IL-18 fusion DNA protects against, and reverses estab-
lished, airway hyperresponsiveness in an animal model of
asthma [241]. On the other hand, in other animal mod-
els, administration of IL-18 enhances antigen-induced
increase in serum IgE and Th2 cytokines and airway eosi-
nophilia in part by increasing antigen-induced TNFα pro-
duction [242,243]. This suggests that IL-18 may
contribute to the development and exacerbation of Th2-
mediated airway inflammation in asthma [244,245].
The serum levels of IL-18 are higher in asthmatic patients
[246] and increase further during exacerbations (and
decrease during the stable phase) compared with normal
subjects [247]. Decreased levels of IL-18 in sputum and
BAL from asthmatic patients compared to normal con-
trols have also been reported [248,249]. There are no clin-
ical studies on the effect of the administration of human
recombinant IL-18 and/or IL-18 antagonists to asthmatic
patients.
Class II family of cytokine receptors
Class II family of cytokine receptors (CRF2) now includes
12 proteins: a new human Type I IFN, IFN-κ; molecules
related to IL-10 (IL-19, IL-20, IL-22, IL-24, IL-26); and the
IFN-λ proteins IFN-λ1 (IL-29), IFN-λ2 (IL-28A), and IFN-
λ3 (IL-28B), which have antiviral and cell stimulatory
activities reminiscent of type I IFNs, but act through a dis-
tinct receptor and are designated as type III IFN by the
nomenclature committee of the International Society of
Interferon and Cytokine Research [250,251]. In response
to ligand binding, the CRF2 proteins form heterodimers,
leading to cytokine-specific cellular responses and these
diverse physiological functions are just beginning to be
explored. The ligand-binding chains for IL-22, IL-26, and
IFN-λ are distinct from that used by IL-10; however, all of
these cytokines use a common second chain, IL-10 recep-
tor-2 (IL-10R2; CRF2-4), to assemble their active receptor
complexes. Thus, IL-10R2 is a shared component in at
least four distinct class II cytokine-receptor complexes. IL-
10 binds to IL-10R1; IL-22 binds to IL-22R1; IL-26 binds
to IL-20R1; and IFN-λ binds to IFN-λR1 (also known as
IL-28R) [253-256]. The binding of these ligands to their
respective R1 chains induces a conformational change
that enables IL-10R2 to interact with the newly formed lig-
and-receptor complexes. This in turn activates a signal-
transduction cascade that results in rapid activation of sev-
eral transcription factors, particularly STAT3 [252] and to
a lesser degree, STAT1 [253-256].
IL-19 modulation and asthma
IL-19 belongs to the IL-10 family, which includes IL-10,
IL-19, IL-20, IL-22, IL-24 [(melanoma differentiation-
associated gene-7 (MDA-7)], and IL-26 (AK155). The IL-
19, IL-20, and IL-24 genes are on chromosome 1q31–32,
a region that also contains the IL-10 gene. The two other
IL-10-related cytokines, IL-22 and IL-26 genes are on chro-
mosome 12q15, near the IFN-γ gene [252]. IL-19 and IL-
24 bind to the type I IL-20R complex which is a het-
erodimer of two previously described orphan class II
cytokine receptor subunits: IL-20R1 [IL-20Rα or cortico-
tropin-releasing factor (CRF) 2–8], and IL-20R2 [IL-20Rβ
(DIRS1)] [252,257]. In addition, IL-20 and IL-24 but not
IL-19, bind to type II IL-20R complex, composed of IL-
22R1 and IL-20R2 [252]. In all cases, binding of the lig-
ands results in STAT3 phosphorylation [252].
The IL-19 gene is up-regulated in monocytes by LPS and
GM-CSF [258] and, in turn, IL-19 induces the production
of IL-6, TNF-α and oxidants in these cells [259]. IL-19 can
also induces apoptosis in monocytes [259]. IL-19 also
induces the Th2 cytokines IL-4, IL-5, IL-10, and IL-13 pro-
duction by activated T cells [257,260]. In vitro, A2B adeno-
sine receptors induce IL-19 from bronchial epithelial cells,
resulting in TNF-α release [261].
The serum level of IL-19 in patients with stable asthma is
increase compared with healthy controls [260]. In an ani-
mal model of asthma there is increased IL-19 expression
and transfer of the IL-19 gene into healthy mice up-regu-
lated IL-4 and IL-5, but not IL-13, however, IL-19 up-reg-
ulated IL-13 in “asthmatic” mice [260]. The role of IL-19
blockers in asthma needs to be explored.
IL-21 modulation and asthma
The interleukin-2 family of cytokines includes IL-2, IL-4,
IL-7, IL-9, IL-13, IL-15 and IL-21. The IL-21 gene is located
on human chromosome 4q26-27, near the IL-2 gene. In
humans IL-21 is produced almost exclusively by CD4+
Th1 and Th2 cells. There is very little expression of IL-21
in activated CD8+ cells [262]. The IL-21 receptor complex
is a heterodimer containing the IL-21R and the common
cytokine receptor γ chain (γc) of the IL-2, IL-4, IL-7, IL-9,
and IL-15 receptors [263]. IL-21 binding stimulates activa-
tion of Janus kinase (JAK)1/JAK3 and then preferentially
activates STAT-1 and STAT-3 [263]. In addition, IL-21
enhances STAT4 binding to the IFN-γ promoter.
IL-21 modulates the proliferation and differentiation of T
cells towards a Th1 phenotype and also stimulates B cells,
NK cells, and dendritic cells [262,263]. In addition, IL-21
also stimulates IgG1 production and decreases IgE pro-
duction [264]. Thus, IL-21 may be a critical cytokine
maintaining low IgE levels under physiological and path-
ological conditions and importantly in support of this IL-Page 16 of 29
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and IgE producing B cell expansion [265]. Interestingly,
IL-21 knockout and IL-21R knockout animals are healthy
and fail to acquire spontaneous inflammatory diseases
[264,266].
IL-21 is also a potent stimulator of cell-mediated immu-
nity (effector CD8+ T and NK cells) and it has a potent
anti-tumour activity in many animal models [262,267]
and ZymoGenetics (http://www.zymogenetics.com.) is
developing IL-21 for the treatment of cancer.
IL-21 administration in an animal model of asthma
reduces titres of antigen-specific IgE and IgG1 antibodies,
as well as airway hyperresponsiveness and lung eosi-
nophil recruitment [262]. Thus, IL-21 signalling modula-
tion may be useful for the treatment of asthma [268].
IL-22 modulation and asthma
The IL-22 gene (and also the IL-26 gene) is located on
human chromosome 12q. The IL-22 heterodimeric recep-
tor is composed of the IL-22R1 (CRF2–9/IL-22R subunit
)and the IL-10R2 to generate the IL-22 receptor complex,
or with IL-20R2 to yield another receptor complex for IL-
20 and IL-24 [269]. In addition to its cellular receptor, IL-
22 binds to a secreted member of the class II cytokine
receptor family, which is called IL-22BP, a soluble recep-
tor which is a naturally occurring IL-22 antagonist.
There are several lines of evidence connecting IL-22 to
asthma. Interestingly, in vitro long-term (12 days) expo-
sure of human T cells to IL-19, IL-20 and IL-22 down-reg-
ulated IFN-gamma but up-regulated IL-4 and IL-13 and
supported the polarization of naive T cells to Th2-like
cells. In contrast, neutralization of endogenous IL-22
activity by IL-22-binding protein decreased IL-4, IL-13
and IFN-gamma synthesis [270].
IL-22 is induced by IL-9, a Th2 cytokine potentially
involved in asthma (see above) and by LPS in animal
models of asthma [269]. IL-22 induces in vitro and in vivo
expression of several acute phase proteins, β-defensins,
pancreatitis-associated protein (PAP1) and osteopontin
[269]. Some of these proteins are involved in inflamma-
tory and innate immune responses. Inasmuch as IL-22 is
implicated in inflammation, the expression of IL-22BP
should decrease local inflammation. In this light, it is of
interest that IL-22BP expression was detected by in situ
hybridization in the mononuclear cells of inflammatory
infiltration sites, plasma cells, and a subset of epithelial
cells in several tissues including lung [271]. Thus, IL-22
signalling modulation may be useful for the treatment of
asthma.
IL-23 modulation and asthma
IL-23 and IL-27 are heterodimeric cytokines functionally
and structurally related to IL-12. Along with two other
cytokines, CLC/soluble CNTFR and CLC/CLF-1, IL-12, IL-
23, and IL-27 compose the IL-12 cytokine family [272].
IL-23 is a dimer composed of the IL-12p40 subunit and
the IL-12p35-related molecule p19 and is produced
mainly by macrophages and dendritic cells. The het-
erodimerized IL-23 receptor is composed of a shared IL-
12 receptor beta 1 (IL-12Rβ1; p40) and an IL-12Rβ2-
related molecule called IL-23R (p19), expressed in natural
killer and CD3+ CD4+ T cells. At least six spliced isoforms
of IL-23R (IL-23R1 to 6) can be generated through alter-
native splicing (most often through deletion of exon 7
and/or exon 10) [272]. IL-23 is important for the prolifer-
ation of memory type Th1 cells [273] and promotes Th17
differentiation [274,275]. IL-23 is likely, therefore, to be
important for the recruitment and activation of a range of
inflammatory cells that is required for the induction of
chronic inflammation.
The potential role of IL-23 modulation in the pathogene-
sis of asthma has still to be explored.
IL-25 modulation and asthma
A novel IL-17 family cytokine IL-25 (IL-17E) is a product
of activated Th2 cells and mast cells (via an IgE-dependent
mechanism). Interestingly, when systemically adminis-
tered to mice, IL-25 induces IL-4, IL-5 and IL-13 produc-
tion from undefined non-T/non-B cells and then induces
Th2-type immune responses such as blood eosinophilia
and increased serum immunoglobulin E levels [276]. In
addition, IL-25 mRNA is expressed in the lung in an ani-
mal model of asthma and neutralization of the produced
IL-25 by soluble IL-25 receptor decreases antigen-induced
eosinophil and CD4+ T cell recruitment into the airways.
In contrast, overexpression of IL-25 in the lung signifi-
cantly enhances antigen-induced Th2 cytokine produc-
tion and eosinophil recruitment into the airways [276].
Thus, IL-25 may play an important role in enhancing
allergic airway inflammation and is therefore a possible
target for inhibition in the treatment of asthma.
IL-27 modulation and asthma
IL-27 is composed of the Epstein-Barr virus (EBV)-
induced gene 3 (EBI3) protein (this subunit has sequence
homology with IL-12p40) plus the IL-12p35-related pro-
tein p28 [277]. A polymorphism of the IL-27p28 gene is
associated with susceptibility to asthma [278]. Most of the
IL-27 is produced by macrophages and dendritic cells. The
functional IL-27 receptor complex is a heterodimeric
receptor composed of either the IL-27R α chain [WSX-1
(after the WSXWS motif, a characteristic feature of
cytokine receptors in its extracytoplasmic portion) or the
T-cell cytokine receptor (TCCR)], in combination withPage 17 of 29
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CD4+ T lymphocytes and NK cells and ligand binding
leads to STAT1 and STAT3 activation [280]. As has been
observed with other members of the IL-6/IL-12 family, IL-
27 has a double identity as an initiator and as an attenua-
tor of immune responses and inflammation [281]. As
such, IL-27 can function as a proinflammatory cytokine
because it synergises with IL-12 to induce IFN-γ produc-
tion from NK cells and promotes Th1 differentiation
through the induction of T-bet and the activation of
STAT4.
Whilst IL-12 is the most potent inducer of Th1 differenti-
ation and IFN-γ production acting on effector Th1 cells,
chronologically differential roles and differential usage of
IL-12, IL-23, and IL-27 have been proposed. First, IL-27
commits naïve CD4+ T cells to differentiate into Th1 cells
by inducing IL-12Rβ2, then IL-12 acts on committed
effector Th1 cells for IFN-γ production, followed by IL-23
mediating the proliferation of memory Th1 cells [281]. IL-
27 also has anti-inflammatory properties. IL-27 inhibits
(through a STAT1- and STAT3-dependent pathway) the
development of Th17 cells [282,283]. IL-23 also inhibits
the development of the iTreg cells [282]. It is believed that
the activation status of the cells may be the key determi-
nant for the differing effects of IL-27. IL-27 acts on naïve
T cells for IFN-γ production while the same cytokine sup-
presses cytokine production by affecting fully activated
cells [281]. In vitro IL-27 also inhibits Th2 cell differentia-
tion through decreased expression of GATA-3 and subse-
quent reduction in IL-4 production [284,285].
In animal models of allergic asthma knockout of IL-27Rα
chain results in a marked increased of airway hyperre-
sponsiveness, BAL eosinophilia, goblet cell hyperplasia
and serum IgE levels [286]. Production of the Th2
cytokines IL-4 and IL-13 is also augmented in the BAL,
but, surprisingly, IFN-γ production is also enhanced,
albeit to a low level [286]. The role of IL-27 modulation
in human asthma is still unknown.
IL-31 modulation and asthma
IL-31 gene is located on chromosome 12q24.31 and is
predominantly expressed by activated CD4+ T cells, par-
ticularly of the Th2 phenotype [287]. The IL-31 receptor is
an herodimer complex formed by IL-31Rα (gp130-like
protein), a member of the IL-6R group that does not
engage gp130, and the oncostatin M receptor β (OSMRβ)
that is shared with oncostatin M, to form a signaling
receptor complex [287,288]. This receptor is constitu-
tively expressed in lung epithelium and is induced in acti-
vated monocytes [287]. Lung epithelial cells express high
levels of IL-31Rα, OSMRβ and gp130 but despite this IL-
31 can utilize a distinct set of intracellular signaling path-
ways compared to oncostatin M which acts through the
OSMRβ/gp130 complex to produce different functional
effects [289]. This, in the A549 cells, initiates IL-31 signal-
ling that differs from other IL-6 cytokines by the particu-
larly strong recruitment of the STAT3, ERK, JNK, and Akt
pathways. IL-31 is highly effective in suppressing prolifer-
ation by altering expression of cell cycle proteins, includ-
ing up-regulation of p27 and down-regulation of cyclin
B1, CDC2, CDK6, MCM4, and retinoblastoma. A single
STAT3 recruitment site (Tyr-721) in the cytoplasmic
domain of IL-31Ralpha exerts a dominant function in the
entire receptor complex and is critical [289]. IL-31 also
appears to be an important regulator of Th2 responses. IL-
31 transgenic mice, shows pruritis and dermatitis (with an
inflammatory cell infiltrate rich of T lymphocytes similar
to that observed in atopic dermatitis) with lesions in the
skin and dorsal root ganglia [290-292]. Importantly, the
expression of IL-31 is increased in the skin of patients with
atopic dermatitis and correlates with IL-4 and IL-13
expression [293]. In an animal model of asthma antigen
challenge increases the expression of IL-31 in lung epithe-
lium and BAL cells [287]. However, more recent data sug-
gest a novel role for IL-31R signaling in specifically
limiting type 2 inflammation in the lung [294]. In vitro,
macrophages generated from IL-31Rα knockout animal
promoted enhanced allergen-specific CD4+ T cell prolifer-
ation and these cells exhibited enhanced proliferation and
expression of Th2 cytokines, identifying a T cell- and mac-
rophage-intrinsic regulatory function for IL-31R signaling
[294]. In contrast, the generation of CD4+ T cell-mediated
Th1 responses is normal in IL-31R knockout, suggesting
that the regulatory role of IL-31R signaling is limited to
Th2 responses [294]. These data suggest that modulation
of IL-31 expression may be in the future another target for
new drugs for asthma.
IL-33 modulation and asthma
The cytokines of the IL-1 family; IL-1α/β, IL-1Ra, and IL-
18 have been matched to their respective receptor com-
plexes. Recently, the ligand for the most prominent
orphan IL-1 receptor, T1/ST2 [295] was found to be IL-33
[296]. Three distinct types of ST2 (also known as T1, Fit-
1, and DER4) gene products have been cloned; a soluble
secreted form (ST2), a transmembrane receptor form
(ST2L), and a variant form (ST2V). ST2L is preferentially
expressed on Th2 cells [297] and stimulates Th2 cytokine
production in the lung and functions as an important
effector molecule of Th2 (but not Th1) responses
[298,299]. Studies in ST2L-deficient mice have produced
conflicting results [300-302] but suggest that while ST2L
can be bypassed by alternative mechanisms following
multiple antigenic challenges, it probably plays a key role
in the early events involved in the generation of Th2
responses [303]. Interestingly, expression of GATA-3,
CCR3, -4, -8, and ST2L, and the generation of blood eosi-
nophilia, is intact in mice doubly deficient in both IL-4Page 18 of 29
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tive regulator of Toll-like receptor4 -IL-1 receptor signal-
ing maintaining endotoxin tolerance [305].
Additionally, ST2L is able to activate the transcription fac-
tor AP-1; increase phosphorylation of c-Jun, and activate
the MAP kinases c-Jun N-terminal kinase (JNK), p42/p44
and p38.
Anti-T1/ST2 also induces the selective expression of IL-4
but not IFN-γ in naive T cells. Importantly, this effect is
blocked by prior treatment with the JNK inhibitor
SP600125 confirming that JNK as a key effector in T1/ST2
signaling [306]. Furthermore, IL-33 activates NF-κB and
MAP kinases, and drives production of Th2-associated
cytokines from in vitro polarized Th2 cells [295].
In animals, IL-33 treatment induces the expression of IL-
4, IL-5 and IL-13 in the lung [295] and intraperitoneal
injection of IL-33 induces spleen eosinophilia [295].
IL-33 is not only able to elucidate effects through binding
to ST2L but, in a manner analogous to that of IL-1α and
HMGB1, can act directly in the nucleus colocalizing with
mitotic chromatin through an evolutionarily conserved
homeodomain-like helix-turn-helix motif within the IL-
33 N-terminal domain and possesses transcriptional
repressor properties [296].
Soluble ST2 protein levels are elevated in the sera of
patients with asthmatic exacerbation, and correlate well
with the severity of asthma exacerbation [307]. Some
studies suggest that soluble ST2 might have an autoregu-
latory role in animal models of asthma [308]. However, if
signalling via ST2L is in fact only important during the
induction of a Th2 response, then production of soluble
ST2 in response to antigenic challenge when allergic sen-
sitization has already been established seems unlikely to
achieve much in terms of autoregulation. Consistent with
this, in transgenic mice with high serum levels of a soluble
ST2-Ig recombinant protein, which would be expected to
bind to and block the putative ligand, there is minimal
reduction in Th2-dependent pulmonary inflammation
[301,303].
Animal models of allergic asthma have demonstrated an
increased accumulation of lung CD4+/ST2+ Th2 cells
[309] and ST2 knockout animals have a significant
decrease of the production of Th2 cytokines [302]. Mono-
clonal anti-T1/ST2 treatment reduces lung inflammation
and the severity of illness in mice infected with RSV, a
model of Th2-mediated immunopathology of the lung
[310]. These data suggest that modulation of IL-33 expres-
sion and/or action is a potential target for new drugs for
asthma.
Other modulators of the Th1/Th2 balance in 
asthma
Surfactant proteins and asthma
Treating animal models of asthma with surfactant pro-
teins can suppress IgE levels, eosinophilia, pulmonary cel-
lular infiltration and cause a marked shift from a Th2 to a
Th1 cytokine profile [311-313].
However, a natural porcine surfactant preparation (Curo-
surf) given before segmental allergen challenge to mild
asthmatics unexpectedly, augmented the eosinophilic
inflammation 24 hours after allergen challenge. A direct
chemotactic effect of Curosurf was excluded. However,
levels of eotaxin and IL-5 were increased in BAL after
Curosurf treatment, whereas IFN-γ-levels and numbers of
IFN-γ+ T cells were decreased. Curosurf had no influence
on spreading and retention of allergen determined by
allergen uptake in mice [314].
Suplatast
Suplatast tosilate is a novel oral anti-asthma compound
that, in vitro, selectively inhibits IL-4 and IL-5 production
from allergen-stimulated human Th2 lymphocytes, but
not IFN-γ production from human Th1 lymphocytes.
Suplatast may also prevent allergen-induced goblet-cell
metaplasia and attenuates inflammatory mediators-
induced eosinophil chemotaxis and eosinophil adhesion
to endothelial cells [8]. Suplatast in a small placebo-con-
trolled clinical trial has been effective as inhaled beclom-
ethasone in improving FEV1 and mean morning PEF. In
patients with moderate asthma (not treated with long-act-
ing bronchodilators), suplatast can significantly decrease
the use of the inhaled glucocorticoid.
In other small clinical trials, suplatast decreased blood
and sputum eosinophils, blood and sputum eosinophil
cationic protein levels, sputum mast cell tryptase levels,
exhaled nitric oxide and airway responsiveness in patients
with mild-moderate asthma or cough-variant asthma
without causing significant side-effects [8].
Immunomodulatory effects of helminth products and 
asthma
Epidemiological studies suggest that helminthic hook-
worms infections may protect subjects from developing
asthma [315]. In an animal model of asthma the applica-
tion of excreted/secreted products (NES) of the helminth
Nippostrongylus brasiliensis together with ovalbumin/
alum during the sensitization period totally inhibited the
development of eosinophilia and goblet cell metaplasia in
the airways and also strongly reduced the development of
airway hyperresponsiveness [316]. Allergen-specific IgG1
and IgE serum levels are also strongly reduced. These find-
ings correlated with decreased levels of IL-4 and IL-5 in
the airways in NES-treated animals [316]. The suppressivePage 19 of 29
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independent of the presence of Toll-like receptors 2 and 4,
IFN-γ, and IL-10. Paradoxically, strong helminth NES-spe-
cific Th2 responses are induced in parallel with the inhibi-
tion of asthma-like responses [316,317].
Th2 responses induced by allergens or helminths share
many common features. However, allergen-specific IgE
can almost always be detected in atopic patients, whereas
helminth-specific IgE is often not detectable and anaphy-
laxis often occurs in atopy but not with helminth infec-
tions [318]. This may be due to T regulatory responses
induced by the helminths or the lack of helminth-specific
IgE. Alternatively non-specific IgE induced by the
helminths may protect from mast cell or basophil degran-
ulation by saturating IgE binding sites. Both of these
mechanisms have been implicated to be involved in
helminth-induced protection from allergic responses
[318]. However a recent study has shown that N. brasil-
iensis antigen (Nb-Ag1) specific IgE could only be
detected for a short period of time during infection, and
that these levels are sufficient to prime mast cells thereby
leading to active cutaneous anaphylaxis after the applica-
tion of Nb-Ag1. Taken together, at least for the model
helminth N. brasiliensis, the IgE blocking hypothesis can
be discarded [319]. However, novel antigens binding
helminth-specific IgE may be identified for other patho-
genic helminths infecting humans. Identifying these anti-
gens may aid in IgE/mast cell-dependent vaccine
development for asthma [318].
Epidemiological studies suggest that a hookworm infec-
tion producing 50 eggs/gram of faeces may protect against
asthma [320]. A pilot dose-ranging study of experimental
human infection with Necator americanus larvae has been
performed to identify the dose of hookworm larvae neces-
sary to achieve 50 eggs/gram of faeces for therapeutic trials
in asthma [321]. A controlled clinical trial with Necator
americanus larvae in asthmatics is now underway [322]
(http://www.nottingham.ac.uk/chs/research/clinicaltri
als.php).
Despite potential safety concerns (cutaneous larva
migrans and/or Loffler's syndrome or other pulmonary
complications [323,324] about this approach, the experi-
mental infection of a small number of human subjects has
been surprisingly safe [321,325].
Conclusions
The current asthma therapies are not cures and symptoms
return soon after treatment is stopped even after long term
therapy. Although glucocorticoids are highly effective in
controlling the inflammatory process in asthma, they
appear to have little effect on the lower airway remodel-
ling processes that appear to play a role in the pathophys-
iology of asthma at currently prescribed doses. The
development of novel drugs may allow resolution of these
changes. In addition, severe glucocorticoid-dependent
and resistant asthma presents a great clinical burden and
reducing the side-effects of glucocorticoids using novel
steroid-sparing agents is needed. Furthermore, the mech-
anisms involved in the persistence of inflammation are
poorly understood and the reasons why some patients
have severe life threatening asthma and others have very
mild disease are still unknown. Considering the appar-
ently central role of T lymphocytes in the pathogenesis of
asthma, drugs targeting disease-inducing Th2 cells are
promising therapeutic strategies [326]. However,
although animal models of asthma suggest that this is fea-
sible, the translation of these types of studies for the treat-
ment of human asthma remains poor due to the
limitations of the models currently used. Since we do not
yet understand the underlying causes of asthma it is
unlikely that therapy will lead to a cure.
The myriad of new compounds that are in development
directed to modulate Th2 cells recruitment and/or activa-
tion will clarify in the near future the relative importance
of these cells and their mediators in the complex interac-
tions with the other pro-inflammatory/anti-inflammatory
cells and mediators responsible of the different asthmatic
phenotypes. Hopefully, it will soon be possible to identify
and manipulate the molecular switches that result in asth-
matic inflammation. This may lead to the treatment of
susceptible individuals at birth or in the early years and
thus prevent the disease from becoming established.
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